List of Excipients in Branded Drug TRIMBOW

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chiesi USA Inc	TRIMBOW	beclomethasone dipropionate/formoterol fumarate/glycopyrrolate	10122-120	ALCOHOL	2030-12-23
Chiesi USA Inc	TRIMBOW	beclomethasone dipropionate/formoterol fumarate/glycopyrrolate	10122-120	HYDROCHLORIC ACID	2030-12-23

Trimbow Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: August 4, 2026

Trimbow is a fixed-dose triple inhaler containing beclometasone dipropionate, formoterol fumarate and glycopyrronium. Its commercial differentiation depends on an extrafine suspension formulation delivered through a pressurized metered-dose inhaler, or pMDI. The current excipient system is deliberately simple: anhydrous ethanol and norflurane, also known as HFA-134a, provide the formulation vehicle and propellant system.[1]

The main commercial opportunities are low-global-warming-potential propellant substitution, lifecycle management of the pMDI platform, device and valve optimization, and generic or regional licensing strategies. Trimbow is authorized in Europe and other non-U.S. markets but does not have an FDA-approved U.S. product with an Orange Book listing. U.S. Paragraph IV and generic-entry analysis therefore does not apply to the marketed product in the same way it applies to an FDA-approved inhaler.

What is Trimbow and which excipients does it contain?

Trimbow is Chiesi Farmaceutici’s extrafine triple therapy inhaler. The active ingredients are:

Component	Pharmacologic class	Function
Beclometasone dipropionate	Inhaled corticosteroid	Anti-inflammatory activity
Formoterol fumarate	Long-acting beta-2 agonist	Bronchodilation
Glycopyrronium	Long-acting muscarinic antagonist	Bronchodilation
Anhydrous ethanol	Co-solvent	Supports drug solubilization and suspension performance
Norflurane, HFA-134a	Propellant	Drives aerosol delivery

The European product information identifies ethanol and norflurane as the excipients in the pressurized formulation.[1] The inhaler is supplied in a pressurized canister with a metering valve and actuator. The formulation is designed to produce an extrafine aerosol, which allows deposition in both the central and peripheral airways.

Trimbow is available in at least two principal strengths in European markets:

Strength per actuation	Beclometasone dipropionate	Formoterol fumarate	Glycopyrronium
Lower strength	87 micrograms	5 micrograms	9 micrograms
Higher strength	172 micrograms	5 micrograms	9 micrograms

The exact licensed strength, indication and dosing schedule vary by jurisdiction. European approvals cover chronic obstructive pulmonary disease, while selected strengths and regimens are also authorized for asthma maintenance treatment.[1]

Why is ethanol commercially important in Trimbow?

Ethanol is not a passive filler in a pMDI formulation. It can affect solubilization, particle formation, suspension stability, vapor pressure, plume geometry and delivered-dose uniformity.

In a suspension or partially solubilized pMDI, ethanol can influence:

• Drug wetting and dispersion
• Particle aggregation
• Valve metering performance
• Spray plume temperature
• Evaporation rate after actuation
• Aerodynamic particle-size distribution
• Chemical stability of the active ingredients
• Dose uniformity throughout canister life

For Trimbow, ethanol optimization is technically complex because three active pharmaceutical ingredients must remain compatible in the same inhalation system. Beclometasone dipropionate, formoterol fumarate and glycopyrronium have different physicochemical properties and dose levels. A change in ethanol concentration can affect each component differently.

This creates commercial value for excipient suppliers and formulation developers that can demonstrate:

1. Robust suspension or solution stability across the product shelf life.
2. Consistent fine-particle dose for all three active ingredients.
3. Low extractables and leachables from the canister, valve and actuator.
4. Acceptable microbial and chemical control for inhalation use.
5. Compatibility with next-generation propellants.
6. Manufacturing processes that preserve dose uniformity at commercial scale.

A minor change in ethanol content may require a new formulation-development package, device studies and comparative in vitro performance data. For a generic or lifecycle product, the value is therefore tied to the entire formulation-device system rather than the excipient alone.

What role does norflurane play in Trimbow?

Norflurane, or HFA-134a, is the propellant that supplies the pressure required to expel the formulation from the canister. It also affects aerosol performance, valve operation and the physical behavior of the formulation during storage.

HFA-134a has been widely used in pMDIs because it has suitable vapor pressure, established pharmaceutical supply chains and a long regulatory history. Its principal commercial weakness is its global-warming potential. The European Environment Agency identifies HFA-134a as a high-global-warming-potential fluorinated gas used in medical inhalers.[2]

The excipient strategy for Trimbow is therefore exposed to the transition away from high-GWP propellants. The most important replacement candidates are:

Propellant candidate	Commercial relevance	Main development issue
HFA-152a	Lower-GWP pMDI propellant	Flammability, device compatibility and manufacturing controls
HFO-1234ze(E)	Very low-GWP candidate	Solubility, vapor pressure and formulation compatibility
Other HFO or HFA systems	Future platform options	Supply, toxicology and regulatory qualification

A propellant change is not a simple excipient substitution. It can alter plume force, particle-size distribution, actuator performance, container pressure, flammability classification and patient handling. For a triple inhaler, the sponsor must also establish that the change does not alter the relative lung delivery of the three active ingredients.

What formulation patents protect Trimbow?

Public product information confirms the composition and delivery technology but does not, by itself, establish the complete patent family covering Trimbow. The relevant intellectual-property categories are likely to include formulation composition, extrafine particle engineering, dose ratios, pMDI delivery, device architecture, manufacturing processes and therapeutic use.

The potentially relevant claim categories are:

Triple active-ingredient formulation claims

These may cover combinations of:

• Beclometasone dipropionate
• Formoterol or a pharmaceutically acceptable salt
• Glycopyrronium or a pharmaceutically acceptable salt
• Ethanol
• HFA propellant
• Defined concentration or particle-size ranges

The commercial value of these claims depends on whether they require the precise Trimbow ratio, a broader active-ingredient combination or a defined extrafine aerosol profile.

Extrafine aerosol claims

Extrathin or extrafine particles can be protected through claims directed to:

• Mass median aerodynamic diameter
• Fine-particle fraction
• Delivered dose
• Regional lung deposition
• Particle size of individual active ingredients
• Ratio of emitted dose to fine-particle dose

These claims can create barriers even where a competitor uses the same active ingredients and excipients. A competitor could avoid infringement by using a different particle-engineering process or a different deposition profile, but it would then need to demonstrate comparable clinical and regulatory performance.

Device and metering-valve claims

The pMDI system may be protected through claims directed to:

• Canister construction
• Metering chamber volume
• Valve materials
• Actuator geometry
• Dose-counter integration
• Suspension homogenization
• Plume-shaping features

Device claims are commercially significant because inhaled-product equivalence is often assessed at the drug-device interface. A formulation that is chemically similar may still require a different actuator or valve system.

Manufacturing-process claims

Potential process claims may cover:

• Micronization of active ingredients
• Co-suspension or co-processing methods
• Filling sequence
• Canister crimping
• Mixing and homogenization
• Control of ethanol concentration
• In-process dose-uniformity testing

Manufacturing claims can restrict supplier substitution even when the finished formulation composition is not covered by a broad composition claim.

How strong is the Trimbow patent estate?

Trimbow’s patent strength is likely to depend less on one broad excipient patent than on a layered combination of formulation, aerosol-performance, device and process rights.

Patent layer	Strategic value	Generic vulnerability
Active-ingredient combination	High if claims cover broad triple therapy	Competitors may design around ratios or salts
Ethanol/HFA formulation	Moderate to high	Alternative propellants or solvent levels may avoid claims
Extrafine particle profile	High where linked to measurable performance	Requires reliable analytical and deposition data
Device and valve	Moderate	Device substitution is possible but costly
Manufacturing process	Moderate	Difficult to detect infringement without discovery
Method of treatment	Variable	Enforceability depends on jurisdiction and label conduct

The strongest practical protection would combine a composition claim with an aerosol-performance limitation and a device or manufacturing claim. A narrow excipient claim alone would provide less durable protection if a competitor can change ethanol concentration, use a different propellant or move to a dry-powder inhaler.

A complete freedom-to-operate review requires family-level analysis in the European Patent Office, United Kingdom, United States and other target markets. Patent status also requires checking continuations, divisionals, national-phase filings, oppositions, amendments and terminal disclaimers. Public regulatory documents should not be treated as a substitute for that patent review.

What is the Orange Book status of Trimbow?

Trimbow does not have the same FDA Orange Book profile as an FDA-approved U.S. inhaled product. The Orange Book lists approved prescription drug products and relevant patent and exclusivity information for products approved under the Federal Food, Drug, and Cosmetic Act.[3]

The commercial implications are:

• No conventional U.S. Orange Book patent-listing strategy has been established for marketed Trimbow.
• A U.S. generic applicant cannot rely on an ordinary Trimbow Orange Book listing to structure a Paragraph IV challenge.
• A future U.S. version could require an abbreviated new drug application, a 505(b)(2) application or another regulatory pathway, depending on the reference product and formulation.
• Device sameness, active-ingredient equivalence and comparative in vitro performance would be central issues.
• U.S. exclusivity and patent exposure must be assessed against any future FDA-approved reference product, not solely against European Trimbow approvals.

When does Trimbow lose exclusivity?

There is no single global Trimbow exclusivity date. The relevant date differs by country and depends on patent families, supplementary protection certificates, pediatric extensions, regulatory exclusivity and settlement agreements.

The product was authorized in the European Union in 2017.[4] EU regulatory data protection and market protection are separate from patent protection. For a centrally authorized medicinal product, the standard EU framework generally provides eight years of data exclusivity and two years of market exclusivity, with a possible one-year extension for a significant new therapeutic indication under qualifying conditions.[5]

The practical timeline is:

Event	Timing or status
European Union authorization	2017
Standard EU data exclusivity	Generally eight years from authorization
Standard EU market protection	Generally two additional years
Potential supplementary protection certificate	Country-specific and patent-dependent
U.S. Orange Book exclusivity	Not established for marketed Trimbow
Generic entry	Depends on country-specific patents, regulatory approval and device equivalence

A regulatory exclusivity calculation should not be used as a substitute for a patent expiry analysis. A patent covering the formulation or device may extend effective market protection after regulatory data protection ends.

Are there Paragraph IV challenges or Trimbow patent litigation?

No conventional U.S. Paragraph IV litigation is associated with an FDA-approved Trimbow reference product because Trimbow does not have the corresponding U.S. Orange Book position.

European litigation risk is different. Potential proceedings could involve:

• National validation of European patents
• European Patent Office opposition
• Supplementary protection certificate disputes
• Infringement of formulation or device claims
• Generic or hybrid application challenges
• Regulatory data or market-protection disputes

The absence of a U.S. Paragraph IV case does not establish freedom to launch in Europe. European generic entry requires country-by-country analysis of patent status, regulatory approval, injunction practice and any confidential or public settlement agreements.

No public settlement agreement should be assumed without a verified court filing, competition-authority record, company disclosure or regulatory document.

What generic-entry risks exist for Trimbow?

The main generic-entry risk is a technically credible triple pMDI that matches the reference product’s emitted dose and aerodynamic performance without copying protected formulation or device claims.

The principal barriers are:

1. Three-way dose uniformity. The applicant must control the relative delivery of all three active ingredients over the canister life.
2. Extrathoracic and peripheral deposition. An extrafine aerosol is difficult to replicate with a different formulation or actuator.
3. Device equivalence. The valve and actuator can materially affect emitted dose and particle distribution.
4. Chemical compatibility. Formoterol, glycopyrronium and beclometasone may show different stability behavior in altered solvent or propellant systems.
5. Manufacturing scale-up. Laboratory formulation performance may not translate to commercial filling and crimping operations.
6. Regulatory evidence. A triple combination may require a more extensive comparative package than a conventional small-molecule oral generic.

A competitor using HFA-152a or HFO-1234ze could create a design-around opportunity, but a propellant change may also create a new patent position for the originator if the reformulated product is protected by composition, device or process claims.

What excipient opportunities exist for suppliers?

The strongest opportunities are in enabling technologies rather than commodity supply.

Low-GWP propellant platforms

A supplier that can provide pharmaceutical-grade HFA-152a or HFO-1234ze with validated impurity profiles could become strategically important to Chiesi and other pMDI manufacturers. The supplier must support toxicology, container compatibility, flammability management and global regulatory filings.

Inhalation-grade ethanol

Ethanol suppliers can differentiate through:

• Low aldehyde and peroxide content
• Tight water control
• Low extractables
• Consistent pharmaceutical-grade purity
• Reliable supply under inhalation manufacturing standards
• Qualification packages for change control

Valve and canister compatibility

Commercial value also exists in coated aluminum canisters, elastomer systems and metering valves compatible with alternative propellants. HFA-152a may require different pressure, flammability and equipment controls than HFA-134a.

Analytical and testing services

Specialized laboratories can support:

• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Fine-particle dose
• Spray pattern and plume geometry
• Leachables and extractables
• Stability under temperature cycling
• Comparative device performance

Licensing and co-development

The most valuable licensing model would combine a low-GWP propellant, inhalation-grade excipient package and compatible device platform. A supplier offering only a new propellant may have limited leverage because the finished product requires reformulation, clinical bridging and regulatory variation work.

How does Trimbow compare with competing triple inhalers?

Trimbow competes with other inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist products, including Trelegy Ellipta from GSK and Trixeo Aerosphere from AstraZeneca. The delivery platforms differ materially.

Product	Active ingredients	Delivery platform	Excipient strategy
Trimbow	Beclometasone, formoterol, glycopyrronium	pMDI	Ethanol and HFA-134a
Trixeo Aerosphere	Budesonide, formoterol, glycopyrronium	pMDI	Propellant-based suspension system
Trelegy Ellipta	Fluticasone furoate, umeclidinium, vilanterol	Dry-powder inhaler	Carrier-based powder platform

Trimbow and Trixeo Aerosphere are exposed to the same broad pMDI propellant-transition issue. Trelegy Ellipta avoids the pMDI propellant problem but depends on dry-powder flow, moisture control, carrier engineering and device resistance.

The competitive choice affects excipient demand:

• pMDI competition favors propellant, ethanol, valve and canister innovation.
• Dry-powder competition favors lactose or other carrier systems, powder engineering and moisture-barrier packaging.
• Triple therapy competition increases the value of analytical methods that establish comparable lung delivery.

What is the FDA regulatory status of Trimbow?

Trimbow is not an FDA-approved U.S. product under the same commercial brand and reference-product framework used for U.S. inhaled therapies. Its principal regulatory footprint is outside the United States, including the European Union and United Kingdom.

For a U.S. commercial launch, a sponsor would need to establish an appropriate FDA pathway and address:

• Active-ingredient quality and characterization
• Device performance
• Comparative aerodynamic particle-size distribution
• Delivered-dose uniformity
• Spray pattern
• Stability
• Extractables and leachables
• Human-factor and usability requirements
• Clinical or pharmacodynamic bridging, where required

A U.S. approval would create a new Orange Book and exclusivity profile. That profile should be analyzed separately from the European Trimbow dossier.

What geographic opportunities exist for Trimbow-related excipients?

The most attractive markets are those with large pMDI use, strong climate-policy pressure and established inhalation manufacturing.

Region	Opportunity
European Union	Propellant transition, lifecycle reformulation and device upgrades
United Kingdom	Independent regulatory and patent strategy after EU authorization
Canada and Australia	Regional pMDI supply and generic development
Latin America	Cost-efficient formulation and local manufacturing
Middle East	Import substitution and distributor licensing
Asia-Pacific	Growth in COPD and asthma, with varied regulatory requirements

Europe is the clearest near-term market for low-GWP pMDI technology because regulatory and environmental pressure is strongest there. Emerging markets may prioritize supply reliability and cost before propellant transition, but local manufacturers can become partners for regional licensing and manufacturing.

Key Takeaways

• Trimbow is an extrafine triple pMDI containing beclometasone dipropionate, formoterol fumarate and glycopyrronium.
• Its disclosed excipients are anhydrous ethanol and norflurane, or HFA-134a.
• Ethanol affects solubilization, suspension stability, dose uniformity and aerosol performance.
• HFA-134a creates a major lifecycle risk because of its high global-warming potential.
• HFA-152a and HFO-1234ze are the leading commercial directions for lower-GWP pMDI reformulation.
• The strongest formulation IP position would combine active-ingredient composition, aerosol-performance, device and manufacturing claims.
• Trimbow has no conventional U.S. Orange Book or Paragraph IV profile as a marketed FDA-approved reference product.
• Generic risk is constrained by three-active-ingredient dose uniformity, extrafine aerosol performance and device equivalence.
• Excipient suppliers have the greatest opportunity in low-GWP propellants, inhalation-grade ethanol, valve systems, canister compatibility and analytical testing.
• European patent and regulatory exclusivity dates must be assessed by jurisdiction and patent family rather than by a single global expiry date.

FAQs

Is Trimbow a suspension or solution inhaler?

Trimbow is a pressurized inhalation formulation designed as an extrafine aerosol system. Its regulatory product information identifies ethanol and norflurane as excipients, while the formulation and device together determine the final aerosol performance.[1]

Can HFA-134a in Trimbow be replaced without clinical studies?

Not automatically. A propellant change can alter dose delivery, particle-size distribution, plume geometry and lung deposition. The regulatory requirements depend on the magnitude of the change, the jurisdiction and the sponsor’s comparative performance package.

Does Trimbow contain lactose?

The pMDI formulation does not use lactose as the primary excipient. Lactose is more commonly associated with dry-powder inhalers, such as carrier-based DPI products.

Which companies compete with Trimbow in triple inhaled therapy?

Key competitors include AstraZeneca’s Trixeo Aerosphere and GSK’s Trelegy Ellipta. Trixeo uses a pMDI platform, while Trelegy uses a dry-powder inhaler, creating different excipient and device-development requirements.

Can a generic manufacturer use the same ethanol and HFA-134a excipient system?

A generic manufacturer may be able to use the same broad excipient categories, but it must address formulation IP, device rights, aerosol performance, stability, regulatory equivalence and any jurisdiction-specific patent restrictions.

References

1. European Medicines Agency. (2024). Trimbow: European public assessment report and product information. https://www.ema.europa.eu/
2. European Environment Agency. (2024). Fluorinated greenhouse gases and substances controlled under the Montreal Protocol. https://www.eea.europa.eu/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
4. European Medicines Agency. (2017). Trimbow: EPAR public assessment report. https://www.ema.europa.eu/
5. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. https://eur-lex.europa.eu/